TY - JOUR
T1 - Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy
AU - East, Jeff
AU - Blanton, Lucas Scott
PY - 2012/2
Y1 - 2012/2
N2 - The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.
AB - The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.
UR - http://www.scopus.com/inward/record.url?scp=84856076005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856076005&partnerID=8YFLogxK
U2 - 10.1128/AAC.05806-11
DO - 10.1128/AAC.05806-11
M3 - Article
C2 - 22123706
AN - SCOPUS:84856076005
SN - 0066-4804
VL - 56
SP - 1081
EP - 1083
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 2
ER -